Bausch + Lomb (NYSE:BLCO) announced today that it appointed Brent Saunders as CEO and chair of its board of directors. Saunders succeeds Joseph C. Papa in the role, effective March 6, 2023. Papa announced his intention to step down in July 2022. When Papa announced his plans to depart, the optical and ophthalmic device maker […]
Bausch + Lomb
Bausch + Lomb buys AcuFocus and its intraocular lens tech
Bausch + Lomb (NYSE:BLCO) announced that its affiliate acquired AcuFocus, a privately held maker of ophthalmic medical devices. The deal remains pursuant to a merger transaction with the parent company of AcuFocus. Neither company disclosed the financial terms of the transaction. AcuFocus develops small aperture intraocular technology. Its portfolio includes the IC-8 Apthera intraocular lens […]
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Bausch Health takes step toward separating Bausch+Lomb
Bausch Health (NYSE:BHC) announced today that it transferred shares of its Bausch + Lomb to an existing subsidiary. The Laval, Quebec–based company transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing, wholly-owned, unrestricted subsidiary of the company. According to a news […]
The biggest medtech personnel moves so far in 2022
In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit. At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. So far in 2022, we’ve already seen a slew of major moves involving some of the space’s most powerful […]
Bausch + Lomb CEO to step down
Bausch + Lomb (NYSE:BLCO) announced today that Joseph C. Papa will step down as the company’s board chair and CEO. The optical and ophthalmic device maker has appointed Thomas W. Ross, Sr., to serve as its chair and has begun the search for a new CEO. Papa will remain as CEO and a member of […]
Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.
Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the therapy to […]
FDA approves Bausch + Lomb dispersive ophthalmic viscosurgical device
Bausch + Lomb announced today that it received FDA approval for its ClearVisc dispersive ophthalmic viscosurgical device (OVD). Laval, Quebec–based Bausch + Lomb — the eye health business unit of Bausch Health — developed the ClearVisc OVD for use in ophthalmic surgery to aid in cataract extraction and intraocular lens (IOL) implantation through the creation […]
Bausch + Lomb wins FDA 510(k) for contact lens coating
Bausch + Lomb said today that it won FDA 510(k) clearance for the use of Tangible Hydra-PEG contact lens coating on new devices, now cleared for use with lenses made from its Boston gas permeable materials. The new clearance will allow the Bridgewater, N.J.-based company to use the coating on its Boston XO, Boston XO2, […]
Analyst downgrades pressure medtech stocks
Several medical device companies took hits yesterday after analysts on Wall Street downgraded their stocks, on a day when the major market indices each closed up a hair, and even medtech firms that enjoyed upgrades came under pressure. Globus Medical (NYSE:GMED) suffered the most after Morgan Stanley analyst David Lewis cut his rating on the stock from […]
Systemic therapy beats Bausch & Lomb implant in NIH uveitis study
Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by […]